Which peptides are legal to compound?
See which peptides are restricted, under review, or on a clearer pharmacy path today.FDA source pages checked hourly.
Join 1,247 people tracking peptide legality.
BPC-157
Recovery and GI-related interest
Currently restricted, but still watched for future review. View details
→TB-500
Recovery-related interest
Currently restricted, but still watched for future review. View details
→GHK-Cu
Skin and recovery-related interest
Currently restricted, but still watched for future review. View details
→Ipamorelin
Growth-hormone-related interest
Currently restricted, but still watched for future review. View details
→Semax
Cognitive-related interest
Currently restricted, but still watched for future review. View details
→KPV
Inflammation- and GI-related interest
Currently restricted, but still watched for future review. View details
→Ibutamoren (MK-677)
Growth-hormone- and appetite-related interest
Currently restricted with no clear near-term easing signal. View details
→CJC-1295
Growth-hormone-related interest
In active review, but not treated as generally available. View details
→Tesamorelin
Growth-hormone-related interest
Currently on the clearer side of compounding access. View details
→PT-141
Sexual-wellness interest
Currently on the clearer side of compounding access. View details
→Retatrutide
Weight-management and metabolic interest
Currently restricted with no clear near-term easing signal. View details
→Cagrilintide
Weight-management interest
Currently restricted with no clear near-term easing signal. View details
→AOD-9604
Metabolic-related interest
In active review, but not treated as generally available. View details
→Cibinetide (ARA-290)
Nerve-related and recovery interest
Currently restricted with no clear near-term easing signal. View details
→Dihexa
Cognitive-related interest
Currently restricted with no clear near-term easing signal. View details
→Emideltide (DSIP)
Sleep-related interest
Currently restricted, but still watched for future review. View details
→Epitalon
Longevity-related interest
Currently restricted, but still watched for future review. View details
→Follistatin
Muscle-related interest
Currently restricted with no clear near-term easing signal. View details
→GHRP-2
Growth-hormone-related interest
Currently restricted, but still watched for future review. View details
→GHRP-6
Growth-hormone-related interest
Currently restricted, but still watched for future review. View details
→Glutathione
Antioxidant-related interest
Currently on the clearer side of compounding access. View details
→Hexarelin
Growth-hormone-related interest
Currently restricted with no clear near-term easing signal. View details
→HGH Frag 176-191
Body-composition interest
Currently restricted with no clear near-term easing signal. View details
→Humanin
Longevity and mitochondrial interest
Currently restricted with no clear near-term easing signal. View details
→IGF-1 LR3
Growth- and recovery-related interest
Currently restricted with no clear near-term easing signal. View details
→Kisspeptin-10
Hormone-related interest
Currently restricted, but still watched for future review. View details
→LL-37
Immune-related interest
Currently restricted with no clear near-term easing signal. View details
→Melanotan II
Tanning and sexual-wellness interest
Currently restricted with no clear near-term easing signal. View details
→MGF
Muscle and recovery-related interest
Currently restricted with no clear near-term easing signal. View details
→MOTS-C
Metabolic-related interest
Currently restricted, but still watched for future review. View details
→NAD+
Cellular-energy interest
Currently on the clearer side of compounding access. View details
→PEG-MGF
Muscle-related interest
Currently restricted with no clear near-term easing signal. View details
→Pinealon
Cognitive and longevity interest
Currently restricted with no clear near-term easing signal. View details
→Selank
Calming and cognitive interest
In active review, but not treated as generally available. View details
→Sermorelin
Growth-hormone-related interest
Currently on the clearer side of compounding access. View details
→SS-31
Mitochondrial and energy interest
Currently restricted with no clear near-term easing signal. View details
→Thymalin
Immune and longevity interest
Currently restricted with no clear near-term easing signal. View details
→Thymogen
Immune-related interest
Currently restricted with no clear near-term easing signal. View details
→Thymosin Alpha-1
Immune-related interest
In active review, but not treated as generally available. View details
→VIP
Inflammation- and respiratory-related interest
A live policy signal suggests the status could still change. View details
→Trust the tracker
Built to answer the two questions most visitors actually have.
Can a pharmacy defend compounding this peptide today, and is there any credible sign that the answer could change soon?
How to read the statuses
Restricted
Currently blocked from routine compounding because the FDA has categorized it as difficult to justify for 503A/503B use.
Under Review
Removed from Category 2 but still awaiting formal FDA compounding guidance after referral to PCAC.
Legal
Currently available through approved or generally compounded pathways.
Where movement is
4 peptides are currently in the clearer review lane, while 17 more still carry a live “watch this” signal in the tracker.
Source and cadence
Kept anchored to FDA posture
March 24, 2026. FDA source pages are checked every hour with AI-assisted monitoring, and changes are reflected in-code so the public site and email alerts can move quickly without editorial drift.
Need a compliant option today? Start with the ingredients that already have a clearer federal footing.
Open the FDA source →